Press Releases

Date Title and Summary Additional Formats
Toggle Summary Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO , May 29, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed
View HTML
Toggle Summary Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
SAN DIEGO , May 20, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W.
View HTML
Toggle Summary Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories
Target Selector™ molecular assay kits are research-use-only (RUO) and offer superior sensitivity compared to NGS-based biomarker analysis for the detection of key actionable oncogene mutations SAN DIEGO , May 14, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Biocept Reports First Quarter 2020 Financial Results
Revenues of $1.4 million increased 41%, revenue per accession increased 27% Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , May 13, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically
View HTML
Toggle Summary Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020
SAN DIEGO , April 29, 2020 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe
Target Selector™ assay kits enable assay developers to leverage Biocept's patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood for liquid biopsy uses SAN DIEGO , April 28, 2020 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples
SAN DIEGO , April 20, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of
View HTML
Toggle Summary Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
SAN DIEGO , April 14, 2020 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
View HTML
Toggle Summary Biocept to Begin COVID-19 Testing
Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO , April 9, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
View HTML
Toggle Summary Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform
Expands global intellectual property portfolio for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and other genetic alterations of interest; increases Biocept's total patent awards for technologies used in molecular diagnostics to 39 SAN DIEGO , April 9,
View HTML